16.95
0.11 (0.65%)
| Penutupan Terdahulu | 16.84 |
| Buka | 16.69 |
| Jumlah Dagangan | 8,089,977 |
| Purata Dagangan (3B) | 3,241,521 |
| Modal Pasaran | 2,282,776,832 |
| Harga / Jualan (P/S) | 19.17 |
| Harga / Buku (P/B) | 9.70 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 11 May 2026 |
| Margin Operasi (TTM) | -788.76% |
| EPS Cair (TTM) | -1.20 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -16.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 22.16% |
| Nisbah Semasa (MRQ) | 6.26 |
| Aliran Tunai Operasi (OCF TTM) | -135.34 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -67.25 M |
| Pulangan Atas Aset (ROA TTM) | -26.79% |
| Pulangan Atas Ekuiti (ROE TTM) | -61.35% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Tango Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | -0.50 |
|
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 12.59% |
| % Dimiliki oleh Institusi | 97.41% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Trv Gp Iv, Llc | 31 Dec 2025 | 7,874,574 |
| Nextech Invest, Ltd. | 31 Dec 2025 | 7,266,081 |
| Logos Global Management Lp | 31 Dec 2025 | 4,200,000 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 27.00 (HC Wainwright & Co., 59.29%) | Beli |
| Median | 19.00 (12.09%) | |
| Rendah | 14.00 (Piper Sandler, -17.40%) | Beli |
| Purata | 19.80 (16.81%) | |
| Jumlah | 5 Beli | |
| Harga Purata @ Panggilan | 15.32 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Guggenheim | 06 Mar 2026 | 20.00 (17.99%) | Beli | 16.95 |
| 06 Feb 2026 | 18.00 (6.19%) | Beli | 12.51 | |
| HC Wainwright & Co. | 06 Mar 2026 | 27.00 (59.29%) | Beli | 16.95 |
| Wedbush | 06 Mar 2026 | 19.00 (12.09%) | Beli | 16.95 |
| Mizuho | 23 Feb 2026 | 19.00 (12.09%) | Beli | 12.73 |
| Piper Sandler | 16 Jan 2026 | 14.00 (-17.40%) | Beli | 13.01 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| CRYSTAL ADAM | - | 12.63 | -54,345 | -686,377 |
| Jumlah Keseluruhan Kuantiti Bersih | -54,345 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -686,377 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 12.63 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| CRYSTAL ADAM | Pegawai | 25 Feb 2026 | Jual automatik (-) | 54,345 | 12.63 | 686,377 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 03 Feb 2026 | Pengumuman | Tango Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 |
| 08 Jan 2026 | Pengumuman | Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor |
| 05 Jan 2026 | Pengumuman | Tango Therapeutics Appoints Sung Lee to Board of Directors |
| 17 Dec 2025 | Pengumuman | Tango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare Conference |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |